OrganiGram Holdings Inc. (OGI) AI Stock Analysis

Organigram Holdings Inc., headquartered in Toronto, Canada, operates through its subsidiaries in the cannabis industry, focusing on the production and distribution of cannabis and cannabis-derived products. Established in 2010, the company serves both medical and adult-use recreational markets in Canada. For medical patients and veterans, Organigram offers products such as cannabis flowers, oils, and vaporizers under various brands. In the adult-use segment, it markets labels like SHRED, Edison Cannabis Co., and Monjour. In addition, the company engages in wholesale activities, supplying plant cuttings, dried flowers, pre-rolls, and derivative-based products across Canada via online and telephone channels.

Annual revenue increased from $79.2M in FY2021 to $145.8M in FY2022, $149.2M in FY2023, $159.8M in FY2024, and $186.1M in FY2025, delivering a 5-year revenue CAGR of 16.5%. Gross margin was -35.9% in FY2021, reached 29.7% in FY2024, and contracted to 3.7% in FY2025. Operating margin remained negative over that period, recording -34.1% in FY2025 alongside net income of -$17.8M. For the trailing twelve months ended June 30, 2026, revenue stood at $309.2M with an operating margin of 5.0% and a profit margin of 28.0%. In the latest quarter, year-over-year quarterly revenue growth was 49.4%.

As of June 30, 2026, cash and short-term investments were $11.7M against total debt of $21.0M, resulting in net debt of $9.3M. Total assets were $820.3M and shareholders' equity stood at $556.5M. The current ratio was 2.61, while the debt-to-equity ratio was 0.04. During FY2025, operating cash flow was -$7.6M and free cash flow was -$24.6M, with capital expenditures of $17.0M. Over 5 years, the company's share count increased 67.4%.

At its last close of $0.93 on October 16, 2026, the company had a market cap of $133.6M and an enterprise value of $175.4M. Its trailing P/E of 2.2x and price-to-sales of 0.4x sit below the median of its US-listed Healthcare peers, which stand at 24.6x and 4.1x, respectively. The enterprise value to EBITDA ratio is 13.4x, above the peer median of 12.0x, while forward P/E is 15.7x versus the peer median of 17.3x. Over the past year, the stock declined 51.0%, underperforming the 16.8% return of the S&P 500 (SPY).

Analyst ratings comprise 3 Strong Buy, 1 Buy, and 1 Hold, with no Sell or Strong Sell recommendations. The mean price target is $8.80, which is 849.3% above the last close of $0.93. For the fiscal year ending September 30, 2026, consensus estimates project EPS of $0.44 on revenue of $349.8M. Across the last 4 quarters, the company recorded 0 EPS beats.

This page is an AI-written research summary of OrganiGram Holdings Inc. (OGI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OGI income statement, OGI balance sheet, OGI key metrics, OGI analyst forecast, OGI chart. See the OGI stock overview for the latest quote and news.